TNXP - Promising Pipeline of Drugs and Institutional Investors are Buying Up Recent Offerings

Summary Significant pipeline of drugs – late stage trials – promising results Substantial institutional buying over the last few weeks, about 30% ownership Will regain NASDAQ compliance in about 6 days Company Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) (Tonix) is a clinical-stage biopharmaceutical company committed to discovering and developing innovative and proprietary new therapeutics that address the needs of patients. We focus on developing small molecules and biologics to treat CNS (pain, neurology, psychiatry, addiction) and immunological (vaccines, immunosuppression, oncology, autoimmune disease) conditions. Pipeline TNX 102: A Fibromyalgia drug in phase 3 trials that already had positive results and it's estimated to be worth 2.8 billion. https://www.globenewswire.com/news-release/2019/05/10/1821834/0/en/Fibromyalgia-Treatment-Market-to-Surpass-US-3-607-3-Million-by-2026-Coherent-Market-Insights.html TNX 102 for Alzheimer’s Currently, there are no FDA-approved treatments for AAD, despite a high disease burden and a need for an effective therapy. TNX-102 SL for the treatment of AAD has been designated by the FDA a Fast Track development program estimated to be worth 3.5 Billion https://www.medgadget.com/2020/09/alzheimers-drugs-market-detailed-overview-market-analysis-manufacturers-and-latest-trends-forecast-to-2030.html TNX 1800 COVID Vaccine moving to human trials soon, already positive results. Uses t-cells which meaning anyone could get this vaccine. https://www.tonixpharma.com/pipeline/tnx-1800-coronavirus-vaccine Skin Test for COVID https://finance.yahoo.com/news/tonix-pharmaceuticals-70m-plans-develop-181512513.html Analysts Price target of $3.00